Feed NTRR
Summary
61 / 100 · Bulios Score
Valuation 76Growth -Profitability 73Quality 43Debt 79Stability 26
What speaks for it
- Out of every 100 USD of revenue, 77 USD is left as net profit.
- You pay 0.3 USD for 1 USD of yearly profit, little for its sector.
What to watch
- For every 100 USD of bills due within a year it has 43 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E today 0.3
Biotechnology industry median
Today you pay 0.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
20222023202420252026
Diluted EPS (USD)
20222023202420252026
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Sales and administration -12 USD
- Taxes and other 6.1 USD
- Net profit 77 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 77 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $76.5K
Debt $115.2K
Free cash flow over 12 months $7.01K
Repaying all its debt would take 16.4 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.